Anzeige
Mehr »
Mittwoch, 07.01.2026 - Börsentäglich über 12.000 News
Wie ein junger Batterie-Spezialist plötzlich zum unverzichtbaren Partner wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41CNR | ISIN: US15117N7012 | Ticker-Symbol: CBO0
Frankfurt
06.01.26 | 08:05
3,160 Euro
-0,63 % -0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMUNON INC Chart 1 Jahr
5-Tage-Chart
IMUNON INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,3603,44006.01.
3,3403,44006.01.

Aktuelle News zur IMUNON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
31.12.25Imunon, Inc. - 8-K, Current Report3
IMUNON Aktie jetzt für 0€ handeln
30.12.25IMUNON raises $7 million in registered direct offering3
30.12.25Imunon, Inc.: IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules4
13.11.25Imunon, Inc. - S-8, Securities to be offered to employees in employee benefit plans10
13.11.25Imunon GAAP EPS of -$1.16 beats by $0.657
13.11.25Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update749R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced...
► Artikel lesen
13.11.25Imunon, Inc. - 10-Q, Quarterly Report-
13.11.25Imunon, Inc. - 8-K, Current Report-
12.11.25Exploring Imunon's Earnings Expectations4
12.11.25Imunon Q3 2025 Earnings Preview3
10.11.25Imunon, Inc.: IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer3
10.11.25Imunon, Inc.: IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer4
04.11.25Imunon, Inc.: IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer5
23.10.25IMUNON präsentiert auf SITC-Tagung neue Daten zur Eierstockkrebs-Therapie16
23.10.25Imunon, Inc.: IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting2
20.10.25Imunon, Inc.: IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer3
14.10.25IMUNON begins Phase 3 trial of ovarian cancer immunotherapy11
14.10.25Imunon, Inc.: IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress3
24.09.25Imunon's Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer15
22.09.25IMUNON reports positive data from ovarian cancer immunotherapy study5
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1